NCT06566170View on ClinicalTrials.gov

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

RecruitingOBSERVATIONAL
Enrollment

6,250

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

February 28, 2033

Study Completion Date

February 28, 2033

Conditions
Alzheimer Disease
Interventions
DRUG

Donanemab

Administered IV

DRUG

Usual Care

Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.

Trial Locations (1)

35805-4046

RECRUITING

Rehabilitation & Neurological Services, Huntsville

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY